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Abstract: Cell therapy is a promising new treatment option for cancer. In particular, mesenchymal
stem cells (MSCs) have shown potential in delivering therapeutic genes in various tumour models
and are now on the verge of being tested in the clinic. A number of therapeutic genes have been
examined in this context, including the death ligand TRAIL. For cell therapy, it can be used in
its natural form as a full-length and membrane-bound protein (FL-TRAIL) or as an engineered
version commonly referred to as soluble TRAIL (sTRAIL). As to which is more therapeutically
efficacious, contradicting results have been reported. We discovered that MSCs producing sTRAIL
have significantly higher apoptosis-inducing activity than cells expressing FL-TRAIL and found that
FL-TRAIL, in contrast to sTRAIL, is not secreted. We also demonstrated that TRAIL does induce the
expression of pro-metastatic cytokines in prostate cancer cells, but that this effect could be overcome
through combination with an AKT inhibitor. Thus, a combination consisting of small-molecule drugs
specifically targeting tumour cells in combination with MSC.sTRAIL, not only provides a way of
sensitising cancer cells to TRAIL, but also reduces the issue of side-effect-causing cytokine production.
This therapeutic strategy therefore represents a novel targeted treatment option for advanced prostate
cancer and other difficult to treat tumours.
Keywords: mesenchymal stem cells; cell therapy; sTRAIL; prostate cancer; AKT; AKTi; IL-6; CXCL5;
ENA-78
1. Introduction
The tumour necrosis factor related apoptosis-inducing ligand (TRAIL), also known as Apo2L,
CD253 or TNFSF10, can induce apoptosis in cancer cells while sparing normal cells. The molecular
basis for the tumour-selective activity of TRAIL remains to be fully defined [1–6]. Unlike conventional
chemotherapeutics, TRAIL induces apoptosis in a p53-independent manner and without substantial
non-specific cellular or DNA damage [7]. Since p53 is frequently inactivated in human tumours, TRAIL
is therefore able to induce apoptosis in cancer cells that are normally hard to treat. These features make
TRAIL a promising agent for anti-cancer therapy.
TRAIL is a member of the TNF superfamily, which forms multimers that interact with cognate
receptors on the cell surface [8–10]. It binds to four membrane-bound death receptors and one soluble
receptor, TRAIL-R1/DR4, TRAIL-R2/DR5, TRAIL-R3/ DcR1, TRAIL-R4/DcR2 and osteoprotegerin
(OPG). TRAIL-R1 and TRAIL-R2 possess a conserved cytoplasmic region termed the death-domain
(DD) that is needed for TRAIL-induced apoptosis [11]. Following binding of TRAIL, a protein complex,
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known as death-inducing signalling complex (DISC) consisting of TRAIL-R1 and/or TRAIL-R2, the
adaptor protein Fas-associated death domain (FADD) and procaspase-8, is formed.
In the DISC, procaspase-8 is activated by a mechanism that involves dimerisation and proteolytic
cleavage [12–14]. In contrast, TRAIL-R3, TRAIL-R4 and the soluble receptor OPG have inhibitory
functions, because they lack the intracellular death-domains, and are therefore regarded as decoy
receptors [8,10,15–18]. Various mechanisms have been described for the action of these decoy
receptors. While TRAIL-R3 prevents the assembly of the DISC, TRAIL-R4 disrupts the formation of
ligand-independent pre-assembled homotrimeric complexes of agonistic TRAIL-receptors [19]. Further,
heterotrimers containing TRAIL-R3 are less active in transmitting apoptosis signals following binding
of TRAIL [20–22].
Activated caspase-8 sets in motion the apoptosis cascade via a number of mechanisms; firstly, it
can directly cleave executioner caspases such as procaspase-3 to the active form of caspase-3. This leads
to apoptosis by proteolytic cleavage of a series of cellular targets giving rise to hallmarks of apoptosis
such as cellular shrinkage, chromatin condensation and nuclear fragmentation [23]. Alternatively, or
in addition, caspase-8 can cleave Bid (BH3-interacting domain death agonist), a proapoptotic protein
from the Bcl-2 family, to a truncated form known as tBid [24]. This tBid then interacts with the Bcl-2
family proteins, Bax and Bak, leading to conformational changes and insertion of these factors into
the outer mitochondrial membrane [25–27]. There, the pro-apoptotic proteins are believed to form
pores giving rise to mitochondrial outer membrane permeabilisation (MOMP). MOMP results in the
release of cytochrome c, Smac/DIABLO and other pro-apoptotic factors into the cytosol. Cytochrome c
amplifies the apoptotic signal emitted by activated caspase-8 via additional caspase-9 activation in the
apoptosome, while Smac/DIABLO releases the X-linked inhibitor of apoptosis protein (XIAP) block on
caspase-9 and executioner caspases, thereby also strengthening apoptosis [28–30].
Even though clinical studies with recombinant TRAIL (rTRAIL) and agonistic antibodies to
TRAIL-receptors have shown that they are safe, only moderate evidence of therapeutic efficacy has
been observed [31–33]. Despite frequent high-dose injections, insufficient bioavailability at the site
of tumour growth has been identified as one of the reasons for lack of efficacy [31–35]. In order to
overcome this problem, gene and cell therapy approaches utilising TRAIL have been tested and shown
to be effective in experimental tumour models [36–41]. In particular, approaches using mesenchymal
stem cells (MSCs) have proven to be successful in this context [42–45]. There are principally two
different options to deliver TRAIL, either as a full-length and membrane bound protein, reflecting the
normal genetic sequence of the TNFSF10 gene, or as an engineered version including the ectodomain
of TRAIL (aa114–281) and a strong signal peptide that ensures effective secretion [42,46].
As MSC-based delivery of TRAIL is about to be tested in clinical trials, it is important to identify
optimal versions of TRAIL that have the best potential for therapeutic efficacy. Therefore, we compared
cells expressing full-length TRAIL (FL-TRAIL) or soluble TRAIL (sTRAIL) in different experimental
systems and approaches to investigate their capacity to induce cancer cell killing. Furthermore,
we analysed how different forms of TRAIL affect the production of potentially side-effect-causing
cytokines [47–49], and how this problem could be overcome by testing different sensitisation approaches
in TRAIL resistant prostate cancer cells.
2. Results
2.1. Comparison of sTRAIL and FL-TRAIL
TRAIL is a 281 amino-acid long type-II membrane protein. However, when used experimentally
as a recombinant protein, only the soluble ectodomain (usually aa114–281) is expressed and purified.
In cell therapeutic applications, it is possible to use either the full-length, membrane-bound version
(FL-TRAIL) or engineer cells to secrete a smaller, soluble form (sTRAIL). Our goal was to compare the
cell death inducing activities of the two TRAIL types in the context of cell therapy, and to investigate
how other non-apoptotic TRAIL-signalling pathways and outcomes were affected. The FL-TRAIL
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expression construct consisted of the TRAIL cDNA (aa1–281) under the control of the CMV promoter
(Figure 1a). For the sTRAIL construct, the TRAIL ectodomain was fused to an Isoleucine Zipper (ILZ)
for trimerisation, the signal peptide of the human Fibrillin gene to provide effective secretion, and a
Furin cleavage site to release the ILZ-sTRAIL protein into the extracellular space (Figure 1a).
Figure 1. FL-TRAIL and sTRAIL are expressed in HEK293 cells, but only sTRAIL is secreted into
the supernatant. (a) Schematic depiction of full length, membrane bound TRAIL (FL) and soluble
TRAIL (sT) expression cassettes including depiction of the localisation of the two TRAIL forms when
expressed in cells. The full-length version is the TRAIL cDNA corresponding to aa1-aa281 containing a
cytoplasmic part (C), transmembrane region (TM) and the extracellular domain. The sTRAIL construct
consists of a hFIB heterologous signal peptide, a Furin cleavage site (Furin CS), an Isoleucine Zipper
(ILZ) and the sTRAIL part from aa114–281. Both constructs are under the control of the CMV promoter
within pcDNA3 expression plasmids or adenoviral vectors. (b) HEK293 cells were transfected with
pCDNA3 constructs for EGFP, FL-TRAIL (FL) or sTRAIL (sT). The resulting protein lysates were western
blotted and probed with a TRAIL antibody. (c) HEK293 cells were transfected with an empty pCDNA3
plasmid (ctrl), as well as constructs for FL-TRAIL (FL) and secreted TRAIL (sT), respectively. The cells
were then stained with a TRAIL antibody followed by a secondary antibody carrying a PE fluorescent
tag and analysed by flow cytometry. (d) HEK293 cells were transfected with expression constructs
for FL-TRAIL (FL), secreted TRAIL (sT) or an empty plasmid (ctrl). After 48 h the supernatants were
filtered through a 0.45 µm filter and the resulting filtrates used for a TRAIL ELISA. Values represent
mean ± SE.
Both constructs were transfected into HEK293 cells and a western blot with respective whole
cell protein extracts showed FL-TRAIL and sTRAIL running at the expected different molecular
weights (Figure 1b). These results indicate that in sTR−AIL expressing cells a substantial amount of
sTRAIL still resides inside of the cells or is associated with the membrane. To further explore this, we
carried out flow cytometric analyses of the cells and found similar TRAIL signals on the surface of
FL-TRAIL and sTRAIL expressing cells suggesting that significant levels of sTRAIL are displayed on
the cell membrane before it is cleaved (Figure 1c). Thus, using sTRAIL in cell therapeutic applications
potentially combines the advantages of FL-TRAIL, achieving high TRAIL concentrations focused
around the vicinity of the cell therapy vehicle with the wider reaches of the secreted molecule. Finally,
we measured the TRAIL concentrations in supernatants of FL-TRAIL and sTRAIL expressing 293 cells.
After filtration through a 0.45 µm filter, the supernatants were applied to a TRAIL ELISA. The results
demonstrate that only sTRAIL expressing cells gave rise to detectable TRAIL levels in the cellular
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supernatants (Figure 1d). Our findings that FL-TRAIL is not secreted or released are in contrast to some
previous reports [50,51]. Therefore, we sought to find out the possible reasons behind this discrepancy.
2.2. Apoptotic Cells Release TRAIL-Containing Cellular Fragments Mimicking Secretion
First, we analysed how different methods of clearing the cell supernatant of cell debris affected the
results of the TRAIL ELISA. We transfected HEK293 cells with the FL-TRAIL and sTRAIL constructs,
respectively. Then, either the unprocessed crude supernatants, cleared supernatants by sedimentation
of cell debris through centrifugation, or cleared supernatants by filtration through a 0.45 µm filter were
applied to a TRAIL ELISA. FL-TRAIL gives rise to cellular particles containing TRAIL that can be
detected in the supernatant. Centrifugation, to some degree, and filtration completely removes these
particles and the TRAIL signal, whereas sTRAIL is not affected by these clearing methods (Figure 2a).
Figure 2. In apoptosis-sensitive, FL-TRAIL expressing cells, TRAIL appears in the supernatant owing to
apoptosis, but not secretion (a) HEK293 cells were transfected with an empty plasmid (ctrl), a FL-TRAIL
construct (FL) or an sTRAIL (sT) construct. The resulting medium supernatants were either taken as
crude supernatants (c), centrifuged (s) or filtered through a 0.45 µm filter (f) before TRAIL levels were
measured by ELISA (b) Apoptosis was measured in HEK293 and CHO cells that were transfected with
an empty plasmid (ctrl), an FL-TRAIL construct (FL) or an sTRAIL construct (sT). (c) CHO cells were
transfected with pCDNA3 constructs expressing FL-TRAIL (FL), sTRAIL (sT) or EGFP. The resulting
protein lysates were subjected to western blotting. The membrane was then probed with a TRAIL
antibody. (d) CHO cells were transfected with an empty plasmid (ctrl), a FL-TRAIL construct (FL) or
an sTRAIL (sT) construct. The resulting medium supernatants were either taken as crude supernatants
(c), centrifuged (s) or filtered through a 0.45 µm filter (f) before TRAIL levels were measured by ELISA.
Values represent mean ± SE.
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It is hypothesised that basal, transfection- or TRAIL-induced apoptosis led to the generation of
TRAIL-containing cellular fragments from dead cells that were detected in the FL-TRAIL samples.
To test this, TRAIL resistant CHO cells (Figure 2b) were used for the production of the two different
TRAIL versions (Figure 2c). After transfection and processing of the supernatants in the described
manner the samples were again applied in their crude, centrifuged or filtered form to a TRAIL ELISA.
Importantly, even crude supernatants from FL-TRAIL transfected CHO cells contained almost no
detectable TRAIL (Figure 2d), indicating that indeed TRAIL-induced apoptosis in HEK293 cells (and
possibly other TRAIL-sensitive producer cells) can result in the appearance of TRAIL in the supernatant.
It seems that the detection is caused by TRAIL-containing debris from apoptotic cells present in the
culture. The TRAIL signal can be removed by centrifugation and filtration demonstrating it is not
proteolytically cleaved and secreted, in contrast to the engineered sTRAIL. Next, we wanted to confirm
these findings in highly relevant MSCs as they hold great promise as a cell therapeutic delivery vehicle
in cancer.
2.3. MSC.sTRAIL Exhibits More Potent Effects on 2D- and 3D-Cultures of Cancer Cells than MSC.FL-TRAIL
We used adenoviral vectors expressing FL-TRAIL or sTRAIL to transduce mouse and human
MSCs, generating MSC.FL-TRAIL and MSC.sTRAIL. Subsequently, we analysed crude, centrifuged
or filtered culture supernatants by TRAIL ELISA. There was no detectable level of TRAIL in any of
the supernatants from the FL-TRAIL samples, whereas sTRAIL was secreted to substantial levels
(Figure 3a,b). This could also be achieved in different types of MSCs, including those derived from
adipose tissue, bone marrow, and umbilical cord (Figure 3c). The fact we did not observe any TRAIL
in the supernatant of the FL-TRAIL samples can be explained by their resistance to TRAIL (Figure 3d).
Thus, in principle MSCs are good cell therapy vehicles for TRAIL, as they do not succumb to their own
molecular armoury.
We went on to further test and compare MSC-produced FL-TRAIL with sTRAIL by testing them
on the human colorectal cancer cell line HT-29. The results show that the supernatants of MSC.sTRAIL
caused a decrease in survival (Figure 3e) and a corresponding increase in apoptosis (Figure 3f), whereas
the MSC.FL-TRAIL supernatants exerted no effects on HT-29 cells. These results were also confirmed
by transwell co-cultures (Figure 3g,h). Mixing of HT-29 cells with MSC.FL-TRAIL or MSC.sTRAIL, at a
ratio of 10:1, resulted in an increase in cell death in both cases, but with a significantly greater effect for
MSC.sTRAIL (Figure 3i,j). Next, MSC.FL-TRAIL and MSC.sTRAIL were tested on a second colorectal
cancer cell line, Colo205. Again, while MSC.FL-TRAIL induced apoptosis in this line, the effect was far
greater with MSC.sTRAIL (Figure 3k). In conclusion, MSC-delivered sTRAIL appears to be superior
compared to FL-TRAIL when mixed with cancer cells, and MSC.FL-TRAIL showed no evidence of
TRAIL secretion. Therefore, we went on to test MSC.sTRAIL on more difficult to treat cancer cells.
Figure 3. Cont.
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Figure 3. MSC.sTRAIL induces higher apoptosis levels in colorectal cancer cells than MSC.FL-TRAIL.
(a) Murine MSCs (mMSCs) were transduced with a control adenoviral vector (ctrl), a vector expressing
FL-TRAIL (FL) or a vector expressing sTRAIL (sT). The resulting medium supernatants were either taken
as crude supernatants (c), centrifuged (s) or filtered through a 0.45 µm filter (f) before TRAIL levels were
measured by ELISA. (b) Human MSCs (hMSCs) were transduced with a control adenoviral vector (ctrl), a
vector expressing FL-TRAIL (FL) or a vector expressing sTRAIL (sT). The resulting medium supernatants
were either taken as crude supernatants (c), centrifuged (s) or filtered through a 0.45 µm filter (f) before
TRAIL levels were measured by ELISA. (c) Different types of MSCs (adipose tissue-derived - AT, bone
marrow-derived - BM, and umbilical cord-derived - UC) were transduced with a control adenoviral
vector (ctrl), a vector expressing FL-TRAIL (FL) or a vector expressing sTRAIL (sT). The resulting
medium supernatants were passed through a 0.45 µm filter before TRAIL levels were measured by
ELISA. (d) Apoptosis was measured in different types of MSCs, adipose tissue-derived (AT), bone
marrow-derived (BM) and umbilical cord-derived (UC) and mouse (mMSC) MSCs that were transduced
with a control adenoviral vector (ctrl), a vector expressing FL-TRAIL (FL) or a vector expressing sTRAIL
(sT). (e) Survival was measured in HT-29 cells after exposure to supernatants from MSC.FL-TRAIL (red)
and MSC.sTRAIL (yellow) at increasing concentrations of sTRAIL. For MSC.FL-TRAIL supernatants
equal volumes of supernatant were used for each corresponding sTRAIL concentration. (f) Apoptosis
was measured in HT-29 cells after exposure to supernatants from MSC.FL-TRAIL (red) and MSC.sTRAIL
(yellow) at increasing concentrations of sTRAIL. For MSC.FL-TRAIL supernatants equal volumes of
supernatant were used for each corresponding sTRAIL concentration. (g) Survival was measured in
HT-29 cells that were co-cultured with control MSCs (ctrl), MSC.FL-TRAIL (FL) or MSC.sTRAIL (sT) in
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24-well plates fitted with transwell tissue culture inserts. (h) Apoptosis was measured at 24 h and 72 h
in HT-29 cells. For this HT-29 cells were co-cultured with control MSCs (ctrl), MSC.FL-TRAIL (FL) or
MSC.sTRAIL (sT) in 24-well plates fitted with transwell tissue culture inserts. (i) Morphologically altered
cells were measured by flow cytometry (changes in FSC/SSC) after mixing HT-29 cells with control
MSCs (ctrl), MSC.FL-TRAIL (FL) or MSC.sTRAIL (sT) at a ratio of 10:1. (j) Apoptosis measurements of
HT-29 cells mixed with control MSCs (ctrl), MSC.FL-TRAIL (FL) or MSC.sTRAIL (sT) at a ratio of 10:1.
(k) Apoptosis measurements of Colo205 cells mixed with control MSCs (ctrl), MSC.FL-TRAIL (FL) or
MSC.sTRAIL (sT) at different ratios (5:1; 10:1; 100:1). Representative images of Colo205 cells mixed
with control MSCs (ctrl), MSC.FL-TRAIL (FL) or MSC.sTRAIL (sT) are shown on the right side of the
panel. MSCs are pointed out by blue arrows, apoptotic cells by red arrows. Scale bar is 30 µm. Values
represent mean ± SE.
2.4. Docetaxel can Sensitise TRAIL-Resistant Prostate Cancer Cells to TRAIL-Induced Apoptosis
Prostate cancer cells are resistant to TRAIL-induced apoptosis (Figure 4a), but several ways have
been described to sensitise cells to this molecule [52]. From a therapeutic standpoint it is beneficial to
choose combinations that include clinically used treatments or specifically targeted drugs. For prostate
cancer the regular chemotherapy is docetaxel or related compounds [53]. Docetaxel is part of the
chemotherapy drug class of taxanes and is a semi-synthetic analogue of Taxol, which is extracted from
the bark of the rare Pacific yew tree. Docetaxel is produced from a chemical, derived from the European
yew tree which is more plentiful and renewable [54]. We used three different prostate cancer cell lines
to test docetaxel and TRAIL combinations: PC3, LNCaP and C4-2B. PC3 cells were established from
bone metastasis of a grade IV prostate cancer patient. LNCaP cells are androgen-sensitive human
prostate adenocarcinoma cells derived from lymph node metastasis. C4-2B cells are a more aggressive
derivative subline of LNCaP cells and were generated by passaging through nude mice.
When we co-treated these prostate cancer cells lines with docetaxel and rTRAIL we found that all
three could be sensitised to TRAIL-induced apoptosis (Figure 4b–d). The effect was most prominent
in PC3 and LNCaP cells (Figure 4b,c), whereas C4-2B cells (Figure 4d) exhibited higher docetaxel
sensitivity and hence less sensitisation effect. Thus, TRAIL/docetaxel co-treatment might be an option
to increase the efficacy of both agents and reverse TRAIL resistance in prostate cancer and other cancer
types. Docetaxel did not lead to an increase in TRAIL-receptor surface expression (Supplementary
Figure S1a) as many other chemotherapeutic drugs do [55,56]. Notwithstanding, the treatment regime
can make these tumour types amenable to MSC.sTRAIL treatment. However, it has recently been
reported that TRAIL and/or chemotherapeutic drugs can also have detrimental effects in the form
of cytokines being induced in response to treatment [48,57]. Therefore, we tested whether TRAIL
induces cytokines in TRAIL-resistant prostate cancer cells and whether docetaxel can repress this
potential induction.
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Figure 4. Docetaxel can sensitise TRAIL-resistant prostate cancer cells to the apoptosis-inducing effects
of TRAIL. (a) PC3, LNCaP and C4-2B cells were treated with increasing concentrations of rTRAIL
before apoptosis was measured. (b) PC3 cells were treated with increasing concentrations of docetaxel
as indicated or treated with docetaxel/TRAIL mixes. TRAIL was used at 5 ng/mL. (c) LNCaP cells were
treated with increasing concentrations of docetaxel as indicated or treated with docetaxel/TRAIL mixes.
TRAIL was used at 5 ng/mL. (d) C4-2B cells were treated with increasing concentrations of docetaxel
as indicated or treated with docetaxel/TRAIL mixes. TRAIL was used at 5 ng/mL. Values represent
mean ± SE.
2.5. TRAIL Induces CXCL5/ENA-78 and IL-6 in Prostate Cancer Cells, which cannot be Blocked by
Docetaxel Co-treatment
When we treated PC3 cells with rTRAIL and applied the medium supernatant to a cytokine
antibody array, containing antibodies against 42 cytokines, we found CXCL5/ENA-78 and IL-6
to be up-regulated when compared to untreated cells (Figure 5a and Supplementary Table S1).
CXCL5/ENA-78 and IL-6 are cytokines that have been associated with tumour progression and have
therefore the potential to cause serious side effects [58]. TRAIL-induced CXCL5/ENA-78 expression
was confirmed by ELISA, which demonstrated that it is increased in a TRAIL-dose dependent manner
(Figure 5b). Similarly, an IL-6 ELISA demonstrated that addition of TRAIL to PC3 cells increased IL-6
levels in the supernatant in a dose dependent manner (Figure 5c). MSC-produced sTRAIL also led to
CXCL5/ENA-78 (Figure 5d) and IL-6 (Figure 5e) induction as measured by ELISA. When we mixed
CHO cells expressing FL-TRAIL or sTRAIL with PC3 cells, CXCL5/ENA-78 was not induced (Figure 5f),
whereas the IL-6 levels were increased (Figure 5g). Although we used CHO cells in these experiments to
avoid interference from MSC-derived factors, these results point to a potential benefit of cell-delivered
TRAIL. However, to address a potential worst-case scenario we continued to use rTRAIL and sTRAIL
to investigate whether co-treatment with docetaxel could prevent the TRAIL-dependent induction of
the two cytokines. Co-treatment of rTRAIL and docetaxel, previously shown to enhance apoptosis
(Figure 4), was not able to block the increased production of either CXCL5/ENA-78 (Figure 5h) nor IL-6
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(Figure 5i). Similarly, sTRAIL from MSCs also induced CXCL5/ENA-78 (Figure 5j) and IL-6 (Figure 5k),
but docetaxel again could not inhibit this increase in cytokine production (Figure 5j,k).
Figure 5. TRAIL induces the expression of CXCL5/ENA-78 and IL-6 that cannot be prevented by
docetaxel co-treatment. (a) Cytokine arrays of untreated PC3 cells and PC3 cells treated with rTRAIL.
The diagram on the right shows the quantification of the factors that were induced by rTRAIL (>50%).
(b) CXCL5/ENA-78 ELISA results of supernatants from PC3 cells (u) and PC3 cells treated with
increasing concentrations of rTRAIL. (c) IL-6 ELISA results of supernatants from PC3 cells (u) and
PC3 cells treated with increasing concentrations of rTRAIL. (d) CXCL5/ENA-78 ELISA results of
supernatants from PC3 cells (u) and PC3 cells treated with 1 ng/mL sTRAIL from MSCs. (e) IL-6 ELISA
results of supernatants from PC3 cells (u) and PC3 cells treated with 1 ng/mL sTRAIL from MSCs.
(f) CXCL5/ENA-78 ELISA results of supernatants from PC3 cells mixed with control transfected CHO
cells (CHO-ctrl), PC3 cells mixed with FL-TRAIL expressing CHO cells (CHO-FL) and PC3 cells mixed
with sTRAIL expressing CHO cells (CHO-sT). (g) IL-6 ELISA results of supernatants from PC3 cells
mixed with control transfected CHO cells (CHO-ctrl), PC3 cells mixed with FL-TRAIL expressing CHO
cells (CHO-FL) and PC3 cells mixed with sTRAIL expressing CHO cells (CHO-sT). (h) CXCL5/ENA-78
ELISA results of supernatants from untreated PC3 cells (u), PC3 cells treated with docetaxel, treated
with rTRAIL or treated with a mix of docetaxel and rTRAIL. (i) IL-6 ELISA results of supernatants
from untreated PC3 cells (u), PC3 cells treated with docetaxel, treated with rTRAIL or treated with a
mix of docetaxel and rTRAIL. (j) CXCL5/ENA-78 ELISA results of supernatants from untreated PC3
cells (u), PC3 cells treated with docetaxel, treated with sTRAIL from MSCs or treated with a mix of
docetaxel and sTRAIL. sTRAIL was used at 1 ng/mL, docetaxel was used at 12.5 nM. (k) IL-6 ELISA
results of supernatants from untreated PC3 cells (u), PC3 cells treated with docetaxel, treated with
sTRAIL or treated with a mix of docetaxel and sTRAIL. sTRAIL was used at 1 ng/mL, docetaxel was
used at 12.5 nM. Values represent mean ± SE.
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Given the potential problems these cytokines could cause, other combination treatments were
investigated that promote significant TRAIL-induced apoptosis and at the same time block or limit the
concomitant up-regulation of pro-metastatic factors such as CXCL5/ENA-78 and IL-6.
2.6. AKTi can Sensitise Prostate Cancer Cells to TRAIL and Block Cytokine Production
Many prostate cancer cells harbour mutations in the PTEN gene [59]. The protein encoded by
PTEN is a phosphatase negatively regulating the levels of phosphatidylinositol-3,4,5-trisphosphate
thereby dampening the pro-growth PI3K and AKT (also known as PKB) signalling pathways [60]. Thus,
prostate cancer cells with PTEN mutations or deletions have elevated PI3K and AKT/PKB activation
levels, which is likely to bestow survival benefits onto these cells when challenged by physiological
surveillance mechanisms or treatment with chemotherapeutic agents or biologicals such as TRAIL.
Therefore, rTRAIL/PI3K inhibitor (PI3Ki) and rTRAIL/AKT-inhibitor (AKTi) combinations were tested
on PC3, LNCaP and C4-2B cells, all bearing mutations/deletions of PTEN [61]. The results show that
both the AKTi and PI3Ki approaches led to significant sensitisation to TRAIL-induced apoptosis in all
three prostate cancer cell lines, with the exception of the PI3Ki in PC3 cells (Figure 6a–c).
Figure 6. Cont.
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Figure 6. AKTi can sensitise prostate cancer cells to TRAIL and block cytokine production. (a) Apoptosis
was measured in PC3 cells that were treated with increasing concentrations of PI3Ki or AKTi and
co-treated with increasing concentrations of rTRAIL. DMSO is a vehicle control. (b) Apoptosis was
measured in LNCaP cells that were treated with increasing concentrations of PI3Ki or AKTi and
co-treated with increasing concentrations of rTRAIL. DMSO is a vehicle control. (c) Apoptosis was
measured in C4-2B cells that were treated with increasing concentrations of PI3Ki or AKTi and co-treated
with increasing concentrations of rTRAIL. DMSO is a vehicle control. (d) Apoptosis measurement of
LNCaP cells mixed with control MSCs (ctrl), MSC.FL-TRAIL (FL) or MSC.sTRAIL (sT) at different
ratios (50:1; 100:1) either with or without AKTi. (e) LNCaP cells were grown as 3D spheroids and
then treated with supernatants from control MSCs (ctrl), full-length TRAIL (FL) MSCs and sTRAIL
(sT) MSCs plus AKTi, before cell viability was assessed. (f) LNCaP cells were grown as spheroids in
Matrigel and then treated with control MSCs (ctrl), MSC.FL-TRAIL (FL) and MSC.sTRAIL (sT) plus
AKTi, before cell viability was assessed. The right panel shows representative images. Spheroids are
indicated by yellow arrows, MSCs by black arrows. Scale bar is 30 µm. (g) Measurements of survival
of untreated PC3 cells (u), PC3 cells treated with AKTi, treated with rTRAIL or treated with a mix
of AKTi and rTRAIL. A representative image of these measurements is shown on the right side. (h)
CXCL5/ENA-78 ELISA results of supernatants of untreated PC3 cells (u), PC3 cells treated with AKTi,
treated with rTRAIL or treated with a mix of AKTi and rTRAIL. (i) IL-6 ELISA results of supernatants
of untreated PC3 cells (u), PC3 cells treated with AKTi, treated with rTRAIL or treated with a mix of
AKTi and rTRAIL. (j) CXCL5/ENA-78 ELISA results of supernatants of untreated PC3 cells (u), PC3
cells treated with AKTi, treated with sTRAIL (sT) from MSCs or treated with a mix of AKTi and sTRAIL
(sT). (k) IL-6 ELISA results of supernatants of untreated PC3 cells (u), PC3 cells treated with AKTi,
treated with sTRAIL (sT) or treated with a mix of AKTi and sTRAIL (sT). Values represent mean ± SE.
Overall, better results were achieved with AKTi and therefore the AKTi was subsequently tested
in combination with MSC.FL-TRAIL and MSC.sTRAIL. We also confirmed that AKTi was functional in
PC3 cells at the basal level and also when cells were treated with TRAIL and docetaxel (Supplementary
Figure S1b). In the cell-mixing experiments, including AKTi, we found MSC.sTRAIL gave rise to
increased apoptosis in prostate cancer cells, while MSC.FL-TRAIL exerted only marginal effects
(Figure 6d).
Next, we examined the cell death-inducing activities of MSC.FL-TRAIL and MSC.sTRAIL in
two prostate cancer cell 3D models that more closely resemble the three-dimensional nature of a
tumour in vivo. Again, the superior effects of MSC.sTRAIL in combination with AKTi was confirmed
compared to MSC.FL-TRAIL (Figure 6e,f).
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Finally, we wanted to know whether AKTi would be able to halt the TRAIL-induced up-regulation
of CXCL5/ENA-78 and IL-6. Under conditions that result in apoptosis sensitisation and reduced
survival (Figure 6g), AKTi almost completely blocked the TRAIL-induced increase in CXCL5/ENA-78
(Figure 6h), whereas the elevated levels of IL-6 were reduced by approximately 30% (Figure 6i).
Hence, AKTi specifically inhibits the pathways leading to CXCL5/ENA-78 and reduces IL-6 production.
Similarly to rTRAIL, sTRAIL from MSCs also induced CXCL5/ENA-78 (Figure 6j) and IL-6 (Figure 6k)
levels. Co-treatment with AKTi inhibited the increase in CXCL5/ENA-78 production (Figure 6j) and
significantly reduced the increase in IL-6 (Figure 6k). A triple treatment with rTRAIL, AKTi and
Docetaxel did not result in any further improvements in cytokine repression (Supplementary Figure
S1c–d). In conclusion, MSC.sTRAIL acts better in combination with AKTi than MSC.FL-TRAIL on
prostate cancer cells with PTEN mutations/deletions. Hence, this combination can not only achieve a
cancer-specific sensitisation to TRAIL-induced apoptosis, but also concurrently reduces the levels of
potentially tumour-progressive cytokines such as CXCL5/ENA-78 and IL-6.
3. Discussion
Despite disappointing results from the initial clinical trials, the death ligand TRAIL remains
a promising candidate for use in anti-cancer therapies, as it is able to trigger cancer cell death
through its two apoptosis-inducing receptors, TRAIL-R1 and TRAIL-R2 [34,41]. Targeting cancer
cells through receptors on their surface can be advantageous as it provides a good degree of
accessibility and is the underlying principle of several targeted therapies such as Trastuzumab/Herceptin
or Bevacizumab/Avastin [62–65]. Better delivery methods, for example with cells that possess
tumour-infiltrating properties, is a potential approach to afford better therapeutic effects of TRAIL [66,67].
In this context, MSCs have shown great promise in preclinical studies, and clinical trials with MSCs
delivering TRAIL are imminent [68].
For therapies that utilise recombinant TRAIL it is clear that only the extracellular domain of
the protein is needed. For cell therapeutic approaches TRAIL can be displayed as a full-length
membrane protein or produced as an engineered secreted form. Both versions have advantages and
disadvantages. Using membrane-bound TRAIL limits the apoptosis induction to the immediate vicinity
of the delivering cells. This restricts detrimental effects arising from high levels of systemic TRAIL, but
also the therapeutic impact as highlighted by Luetzkendorff et al. [69]. They found that a substantial
number of MSCs expressing FL-TRAIL was required to yield an anti-tumour response. This was
achieved by direct-tumour-injections, whereas systemic application of their FL-TRAIL carrying MSCs
had no effect on the growth of colorectal cancer xenografts owing to a low rate of tumour integration
of MSCs. This is in contrast to several studies with MSCs producing sTRAIL in various cancer
models [42,46,56,70,71]. However, another report noted that MSC-delivery of FL-TRAIL is superior to
soluble TRAIL for cancer therapy [51].
In the present study, we observed that MSCs producing sTRAIL have more potent effects than
cells expressing FL-TRAIL, both in conventional cell culture assays as well as 3D tumour cell spheroids.
This is despite membrane-bound FL-TRAIL being a very strong apoptosis inducer during direct
cell interactions, but for cell therapeutic applications the wider reaching activities of secreted and
diffusing sTRAIL appear to be more important and effective [72]. We found no evidence for FL-TRAIL
being processed and released from the membrane, thus its activity is indeed limited to the immediate
vicinity of the cell therapy vehicle. Instead we discovered that cellular fragments containing TRAIL,
originating from dead cells, can be mistaken for secreted TRAIL. The fact that we could eliminate
the TRAIL signal in supernatants of FL-TRAIL expressing cells by filtration through a 0.45 µm filter
rules out exosomes/extracellular vesicles (EVs) as the carrier of TRAIL, because they would not have
been excluded by the filtration step, given their size of 40–100 nm [73]. Another type of extracellular
vesicle, so called microvesicles (MVs), can be up to 1 µm in diameter, but also smaller vesicles (100 nm)
may bud from the cell surface to form MVs [74]. Thus, it is unlikely that all TRAIL containing MVs
would have been eliminated by filtration. Additionally, when we used cells, that were resistant to
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TRAIL-induced apoptosis, including MSCs, we could no longer detect TRAIL in the supernatants of
FL-TRAIL expressing cells. Together these results suggest that cellular fragments from apoptotic cells
are the source of the detected TRAIL.
In relation to the discrepancies in the observed therapeutic effects of MSC.sTRAIL vs.
MSC.FL-TRAIL, they are reconcilable by the fact that in lung cancer models MSCs with FL-TRAIL
might work very well, as most systemically administered MSCs will infiltrate the lungs in the first
24–48 h, before they are cleared and appear in other tissues including tumours, but in far smaller
numbers [75]. Thus, MSC.FL-TRAIL might be sufficient for lung cancer treatment, but not for other
cancer types. Accordingly, the pending “TACTICAL” clinical trial for lung cancer with MSC-TRAIL
vehicles will be using full-length TRAIL [76].
Irrespective of the form of TRAIL used, the fact that not all tumours are naturally sensitive to
TRAIL remains an issue. This not only limits the therapeutic effects, but also allows cancer cells to
respond with induced cytokine production. Some of these factors are known to have pro-metastatic
activity and could cause serious side effects. It was shown that TRAIL-triggered cytokine secretion from
TRAIL resistant cancer cells is FADD- and caspase-8 dependent. CXCL1, CXCL5, CCL2, and IL-8 were
significantly induced by TRAIL in lung, colorectal and pancreatic cancer cell lines [48,77]. In particular
CCL2 was responsible for monocyte polarisation to myeloid-derived suppressor cells (MDSCs) and
M2-like macrophages. Blocking CCL2 signalling reduced the TRAIL-induced tumour-supportive
immune microenvironment and tumour growth. MDSCs can influence tumour progression in a number
of ways. They are directly implicated in the promotion of metastasis development by participating
in the formation of a pre-metastatic niche, promoting angiogenesis and tumour cell invasion [78].
In addition, tumour associated macrophages (TAMs), and in particular M2-like macrophages have
been associated with early tumour dissemination and progression [79,80]. These findings point to
potential problems with TRAIL-based cancer therapies such as increased cancer cell proliferation and
tumour progression [48]. Similarly, signalling by FasL/CD95L, another member of the death ligand
family, was found to be associated with the production of an array of cytokines and chemokines,
including IL-6, IL-8, CXCL1, MCP-1, and GM-CSF [81].
We found that rTRAIL and sTRAIL induced CXCL5/ENA-78 and IL-6 expression in TRAIL-resistant
prostate cancer cells. CXCL5/ENA-78 is a member of the CXC chemokine family and is known to be
activated by inflammatory cytokines such as interleukin-1 or tumour necrosis factor-alpha [82]. It is
an ELR+ chemokine that can activate CXCR2 and has been described to promote angiogenesis [58].
In addition, the CXCR2/CXCL5 pair has been shown to enhance tumour progression by increasing
the formation, recruitment and suppressive activity of MDSCs [83]. IL-6 is an interleukin that acts
as a pro-inflammatory cytokine, but can also have anti-inflammatory activities as a myokine, i.e.,
when it is activated in response to muscle contraction during exercise for example [84,85]. IL-6 has
multiple effects on tumour progression, of which some are the result of direct action on tumour cells,
while others are the result of its activity on other cells in the tumour microenvironment [86]. It has
a direct growth stimulatory effect on many tumour cells by activating several signalling pathways
including Ras/Erk and STAT-3 [87,88]. IL-6 can also play an important role in promoting metastasis
formation in distal organs by increasing the expression of bFGF, MMP-2, and VEGF, which contribute
to invasion and angiogenesis [89]. Additionally, it has been reported that IL-6 in primary tumours
promotes tumour self-seeding, i.e., the re-colonisation of the tumour of origin by circulating tumour
cells. This process is able to accelerate tumour growth, angiogenesis, and stromal cell recruitment [90],
and self-seeding might be an important contributor to tumour aggressiveness [91]. Taken together these
results suggest that TRAIL can induce cytokines with possible detrimental effects, particularly when a
number of cytokines are concomitantly upregulated and acting with complementarity. Interestingly,
CHO cells expressing FL-TRAIL or sTRAIL, when mixed with PC3 cells, induced IL-6 expression
whereas CXCL5/ENA-78 remained unchanged. While we do not have a mechanistic explanation for
this effect, the results point to important benefits of TRAIL delivered by cell therapy that are worthy to
be studied in more detail in the future.
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The prostate cancer cells utilised in this study, as with many other tumour types, were resistant
to TRAIL and therefore needed a sensitising treatment. This provides the opportunity to combine a
TRAIL-based therapy with standard chemotherapy, which would be good practice for testing a new
experimental cell therapy such as MSC.sTRAIL. Docetaxel is the most commonly used chemotherapy
for men with advanced prostate cancer and synergies with TRAIL have been reported [92]. In this
paper, the authors suggested that the TRAIL sensitisation by Docetaxel was mediated mainly by
phosphorylation of BCL2 by activated JNK. Alternatively, a treatment targeted for the specific cancer
type could be utilised. Advanced prostate tumours, including the PC3 cells that we examined, harbour
mutations/deletions in PTEN that lead to high constitutive PI3K and AKT activation, providing a major
therapeutic opportunity in the form of PI3Ki and AKTi [93]. Indeed, activation of the AKT survival
pathway was demonstrated to contribute to TRAIL resistance and the PI3K inhibitor LY294002, or
knockdown of AKT, sensitised resistant cancer cells to TRAIL [94]. While both, docetaxel and AKTi
approaches worked to increase the TRAIL responsiveness, only a combination treatment of TRAIL
with AKTi blocked the production of TRAIL-induced cytokines.
Thus, MSC-delivered sTRAIL in combination with AKTi (or other appropriate co-treatments) is a
potential future therapeutic approach for advanced prostate cancer and other difficult to treat tumour
types, as it enables TRAIL to induce apoptosis and prevents or reduces the production of harmful
cytokines at the same time.
4. Materials and Methods
4.1. Cell Culture and Reagents
All chemicals, unless otherwise stated, were purchased from Sigma (St. Louis, MO, USA).
Recombinant TRAIL (rTRAIL) was from R&D Systems (Minneapolis, MN, USA). Docetaxel, AKTi
(MK-2206) and PI3Ki (LY294002) were from Stratech (Stratech Scientific, Ely, UK).
The colorectal carcinoma cell lines Colo205 (obtained from Dr. Eva Szegezdi) and HT-29 (ATCC,
Manassas, VA, USA) were cultured in RPMI (Lonza, Basel, Switzerland) and in McCoy’s 5A (Lonza),
respectively. HEK293 cells were grown in DMEM (Lonza) and CHO cells (ATCC) in Ham’s F12. The
prostate cancer cell lines, LNCaP (ATCC), C4-2B (obtained from Dr. Wafa Al-Jamal) and PC3 (ATCC),
were cultured in RPMI medium (Lonza). All media were supplemented with 10% fetal bovine serum
(FBS) (Thermo Fisher Scientific, Waltham, MA, USA), 100 U/mL penicillin and 100 µg/mL streptomycin.
Human bone marrow derived MSCs were from Lonza, human adipose derived stem cells were
from Amsbio (Cambridge, MA, USA) and human umbilical cord derived MSCs were from Promocell
(Heidelberg, Germany). The different human MSCs were cultured in StemMACS MSC Expansion
Medium (Miltenyi Biotec, Bergisch Gladbach, Germany). Murine MSCs were isolated and cultured as
previously described [75]. In experiments where it was stated that MSCs were used, but not further
defined, human bone marrow derived MSCs were used.
4.2. Generation of TRAIL Constructs
The TRAIL full-length (FL-TRAIL) cDNA was cloned by RT-PCR from Jurkat cell RNA [39].
The sTRAIL segment (aa114–281) was amplified by PCR from the FL-TRAIL construct as described
previously [95]. Recombinant E1/E3-deleted adenoviral vectors expressing sTRAIL and FL-TRAIL
(Ad.sTRAIL, and Ad.FL-TRAIL), from the cytomegalie virus (CMV) promoter/enhancer elements were
generated using the ViraPower adenoviral expression system (Thermo Fisher Scientific) as described
earlier [44]. Transductions with adenoviral vectors were carried out as described before [96] at an
MOI of 200 if not described otherwise. Adenovirus harbouring the LacZ gene coding for the bacterial
β-galactosidase gene was used as a control.
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4.3. Transwell co-Cultures
TRAIL expressing MSCs were co-cultured with HT-29 cells in 24-well plates, where HT-29 cells in
the lower chamber are separated from the MSCs in the upper chamber by a semipermeable membrane
(0.4 µm pore size). For this, MSCs were seeded in a 6-well plate and transduced with Ad.sTRAIL or
Ad.FL-TRAIL respectively. 48 h later, the MSCs were harvested and transferred into the chamber
of the transwell-insert (Sarstedt, Nümbrecht, Germany). For further analyses the transwell-inserts
were removed.
4.4. 3D Spheroid Colorimetric Proliferation/Viability Assay
3D Spheroid Colorimetric Proliferation/Viability Assay (Trevigen, Gaithersburg, MD, USA) was
performed according to the manufacturer’s instructions. Briefly, upon completion of spheroid formation,
the LNCaP spheroids were co-treated with 1 µM AKTi, 5 ng sTRAIL or an equal volume of FL-TRAIL
secreting cell supernatant for 3 days before cell viability was assessed.
4.5. 3D Culture
500 cells were resuspended in 40 µL Matrigel (Beckton Dickinson, Franklin Lakes, NJ, USA).
The 3D culture was established for 5 days before the tumoroids were co-treated with 1 µM AKTi and
TRAIL expressing MSCs. Control vector transduced MSCs served as control. Images were taken after
3 days, before cell viability was determined by resazurin reduction.
4.6. Crystal Violet Assay
Cells were seeded at a density of 1 × 104 cells in a 24-well plate. After 24 h the cells were treated
for 3 days. Crystal violet staining was performed as previously described [57]. The crystal violet stain
was solubilised in methanol and the optical density of each well was measured at 570 nm. The average
OD570 of non-stimulated cells was set to 100%.
4.7. ELISA
CHO and 293 cells were Fugene-HD (Promega, Fitchburg, WI, USA) transfected with
pcDNA.FL-TRAIL and pcDNA.sTRAIL. 48 h post-transfection, the supernatants were removed
and filtered through a 0.45 µm syringe filter (Sarstedt) unless otherwise stated. Secreted TRAIL
levels were determined by DuoSet ELISA (Biotechne, Minneapolis, MN, USA), according to the
manufacturer’s instructions. 1 ng sTRAIL, or an equal volume of FL-TRAIL cell supernatant, was used
in further assays unless otherwise stated.
For the IL-6 (Duoset, Biotechne) and CXCL5/ENA-78 ELISA (Duoset, Biotechne), PC3 cells were
seeded and treated with 5 ng TRAIL or 1 ng sTRAIL unless otherwise stated. For combination
treatments, the cells were pre-treated with 10 µM AKTi for 10 min and with 12.5 nM Docetaxel for 6 h
before TRAIL was added for a further 72 h.
CHO cells were transfected with an empty pcDNA3 vector (ctrl), pcDNA.FL-TRAIL and
pcDNA.sTRAIL. After 24 h, cells were washed and trypsinised, then counted and mixed with
PC3 cells at a ratio of 1:5 for 72 h. The resulting supernatants were analysed for CXCL5/ENA-78 and
IL-6 by ELISA.
4.8. Cell Surface Staining and FACS Analyses
Cells were analysed for TRAIL and TRAIL-receptor expression on their cell surface by flow
cytometry. 1 × 106 cells per test were washed with PBS supplemented with 2% bovine serum albumin.
Anti-human TRAIL antibody (Diaclone, Besançon, France), anti-human TRAIL-R1 (Diaclone) and
anti-human TRAIL-R2 (Diaclone) were added for 20 min at 4 ◦C. Following a washing step, the cells
were incubated with rat anti-mouse IgG1 PE (BioLegend, San Diego, CA, USA). An isotype-matched
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immunoglobulin was used as control. After fixation with 2% paraformaldehyde samples were
immediately analysed.
4.9. Apoptosis Assays
For apoptosis measurements, cells were treated 24 h with TRAIL, unless otherwise stated.
In combination treatments with docetaxel, cells were pre-treated with docetaxel for 48 h before TRAIL
was added. Apoptosis was determined 24 h after TRAIL was added. In combination treatments
with AKTi, cells were co-treated with 1 µM AKTi and TRAIL for 24 h. TRAIL expressing cells were
harvested 48 h post transfection/transduction and added to the tumour cells at the indicated ratios.
Apoptosis was determined 24 h later.
DNA hypodiploidy staining: cells including their medium supernatant and PBS wash were
harvested and centrifuged at 1300 rpm for 7 min at 4 ◦C. After washing with PBS, Nicoletti buffer
(Sodium citrate 0.1% (w/v) containing 0.1% Triton X-100 (w/v) and propidium iodide 50 µg/mL) [97,98]
was added to the cell pellets, tubes were vortexed for 10 s at medium speed and left for 1 h in the dark
(4 ◦C). The fluorescence intensity was then measured in a flow cytometer and analysed. Cell death was
also determined by flow cytometry by measuring changes in the forward (FSC) and side scatter (SSC).
4.10. Western Blot
Proteins were separated by SDS-PAGE and transferred onto PVDF membranes (GE Healthcare
Biosciences, Piscataway, NJ, USA). Primary and secondary antibodies were diluted in TBS, 0.1% Tween
and 3% BSA. Bands were visualised with ECL Western blotting substrate (Thermo Fisher Scientific).
Rabbit anti-TRAIL (Peprotech, Rocky Hill, NJ, USA), rabbit anti-phospho AKT and rabbit anti-AKT (Cell
Signaling Technology, Danvers, MA, USA) were used as primary antibodies and peroxidase-conjugated
anti-rabbit antibody (Santa Cruz, Dallas, TX, USA) was used as secondary antibody.
4.11. Cytokine Array
For these studies, supernatants from PC3 cells treated with 5 ng rTRAIL were used. They were
compared to the cytokine levels of untreated PC3 cells. The respective supernatants were diluted
10-fold and applied to human cytokine antibody arrays III (RayBio, Norcross, GA, USA) according to
manufacturer’s instructions. Each cytokine signal was normalised to the internal control and the fold
upregulation in response to rTRAIL was calculated.
4.12. Statistical Analysis
Experimental values are expressed as mean value ± standard error (SE). For significance analyses,
analysis of variance (ANOVA) between groups was used.
5. Conclusions
Our results demonstrate that in the context of cell therapy an engineered, secreted version of
TRAIL has more anti-cancer potency than full-length TRAIL that remains membrane-bound and is not
secreted into the extracellular space. Therefore, in most cases the use of sTRAIL will be more beneficial.
Furthermore, TRAIL resistant prostate cancer cells can be sensitised by AKTi co-treatment, which
also prevents the TRAIL-induced induction of tumour promoting and pro-metastatic cytokines from
the cancer cells, providing an added advantage. This response is specific, as it cannot be afforded by
docetaxel co-treatment, despite being able to sensitise prostate cancer cells to TRAIL-induced apoptosis.
Thus, MSC-delivered sTRAIL in combination with AKTi is a potential option for advanced prostate
cancer with PTEN mutations/deletions, but other combinations may be necessary in a cancer-specific,
or even patient-specific, manner.
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